- Home
- SER vs ANL Comparison
SER vs ANL Comparison
Compare SER & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SER | ANL |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 52.0M |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SER | ANL |
|---|---|---|
| Price | $3.25 | $1.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 15.6K | 13.2K |
| Earning Date | 11-13-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,000.00 | N/A |
| Revenue This Year | $134.46 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.20 | $0.88 |
| 52 Week High | $7.92 | $2.99 |
Technical Indicators
Market Signals| Indicator | SER | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 32.60 | 22.30 |
| Support Level | $3.68 | $1.32 |
| Resistance Level | $4.26 | $1.59 |
| Average True Range (ATR) | 0.27 | 0.16 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 9.61 | 5.70 |
Price Performance
Historical ComparisonAbout SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.